29 September 2016 - CADTH has published its initial take on the reimbursement of Darzalex for patients with multiple myeloma.

CADTH does not recommend the reimbursement of daratumumab for the treatment of patients with multiple myeloma who:

• have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD)
• have failed or are intolerant to a PI and who have failed or are intolerant to an IMiD

The Expert Review Committee was unable to conclude that daratumumab has a net clinical benefit over other treatments.

Read CADTH's initial recommendation for Darzalex